

1644

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)


Application Number	09/155,590
Filing Date	September 30, 1998
First Named Inventor	Jeffrey SCHLOM et al.
Group Art Unit	1644
Examiner Name	G. Ewoldt
Attorney Docket Number	38163-0061

Total Number of Pages in This Submission

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Response to Notice of Non- Compliant Amendment; copy of Notice of Non-Compliant Amendment
RECEIVED FEB 10 2003 TECH CENTER 1600/2900		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	
Signature	
Date	February 6, 2003

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: <input type="text"/>			
Typed or printed name			
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



26633

PATENT TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

84/LS590

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
	9/30/98	Schlom et al	38163-0061

JOHN P ISACSON, ESQUIRE
HELLER EHRMAN WHITE & MCAULIFFE
1666 K STREET NW
SUITE 300
WASHINGTON DC 20006

EXAMINER	
ART UNIT	PAPER NUMBER
	33

DATE MAILED: 1/14/03

Please find below a communication from the EXAMINER in charge of this application
Commissioner of Patent

Notice of Non-Compliant Amendment (37 CFR 1.121)


The amendment filed on 4/22/02 is considered non-compliant because it has not been submitted in the format required under 37 CFR 1.121, as amended on September 8, 2000 (see 65 Fed. Reg. 64603, Sept. 8, 2000, and 1238 O.G. 77, Sept. 19, 2000).

- ☐ 1. The amendment does not include a clean version of the replacement paragraph(s)/section(s). 37 CFR 1.121(h)(1)(ii).
- ☐ 2. The amendment does not include a marked-up version of the replacement paragraph(s)/section(s). 37 CFR 1.121(b)(1)(iii).
- ☐ 3. The amendment does not include a clean version of the amended claim(s). 37 CFR 1.121(c)(1)(i).
- ☐ 4. The amendment does not include a marked-up version of the amended claim(s). 37 CFR 1.121(c)(1)(ii).
- ☒ 5. Other: Amended claims must recite "(amended)" and the number of times amended. See MPEP Appendix, RULES.

Since the response appears to be bona fide, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. **EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).**

Any inquiry concerning this communication should be directed to Examiner G.R. Ewoldt, Art Unit 1644, whose telephone number is 703-308-9805.

Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.


G.R. Ewoldt, Ph.D.
Patent Examiner
December 30, 2002



Attorney Docket No.: 38163-0061

#34/F
gnd
2/11/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 10 2003

TECH CENTER 1600/2900

Applicant(s): Jeffrey SCHLOM et al.

Confirmation No. 8846

Appl. No.: 09/155,590

Examiner: G. Ewoldt

Filing Date: September 30, 1998

Group Art Unit: 1644

Title: MUTATED RAS PEPTIDES FOR GENERATION OF CD8+ CYTOTOXIC
T LYMPHOCYTES

RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT UNDER 37 CFR 1.121

Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants herein respond to the Notice mailed January 14, 2003 (Paper No. 33).

Please amend the captioned application as set forth below. Applicants do not believe there is any fees due or any extension of time required with this filing, but hereby authorize payment if any is required, to firm deposit account no. 08-1641.

IN THE CLAIMS

Please amend claim 34 as set forth below.

34. (5 times Amended) The Pharmaceutical composition according to claims

F1 32 or 33, further comprising a liposome formulation, an antigen presenting cell, or an adjuvant comprising mycobacterial cell wall skeleton and monophosphoryl lipid A.
